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Purpose/Objective(s): Regional failures occur in up to 15% of 
patients treated with stereotactic body radiotherapy (SBRT) for stage 
I/II lung cancer. This report focuses on the management of the unique 
scenario of isolated regional failures.
Methods: Patients treated initially with SBRT or accelerated hypo-
fractionated radiotherapy were screened for curative intent treatment 
of isolated mediastinal failures (IMFs). Local control, regional con-
trol, progression-free survival, and distant control were estimated 
from the date of salvage treatment using the Kaplan–Meier method.
Results: Among 160 patients treated from 2002 to 2012, 12 suffered 
IMF and were amenable to salvage treatment. The median interval 
between treatments was 16 months (2–57 mo). Median salvage dose 
was 66 Gy (60–70 Gy). With a median follow-up of 10 months, the 
median overall survival was 15 months (95% confidence interval, 
5.8–37 mo). When estimated from original treatment, the median 
overall survival was 38 months (95% confidence interval, 17–71 
mo). No subsequent regional failures occurred. Distant failure was 
the predominant mode of relapse following salvage for IMF with a 
2-year distant control rate of 38%. At the time of this analysis, three 
patients have died without recurrence while four are alive and no 
evidence of disease. High-grade toxicity was uncommon.
Conclusions: To our knowledge, this is first analysis of salvage medi-
astinal radiation after SBRT or accelerated hypofractionated radio-
therapy in lung cancer. Outcomes appear similar to stage III disease at 
presentation. Distant failures were common, suggesting a role for con-
current or sequential chemotherapy. A standard full course of external 
beam radiotherapy is advisable in this unique clinical scenario.
Key Words: Lung cancer; Salvage; Regional relapse.
(J Thorac Oncol. 2014;9: 572–576)
Regional relapse after stereotactic body radiotherapy (SBRT) in early-stage lung cancer is seen in up to 10% 
to 15% of patients.1 Inoperable patients with metastases to 
regional lymph nodes (American Joint Committee on Cancer 
Staging 7th edition, N1 or N2) at presentation are treated with 
chemoradiotherapy, and it therefore stands to reason patients 
with regional failures would benefit from a similar treatment.
Despite this logical argument, the successful salvage 
rate after external beam radiotherapy (EBRT) with or with-
out chemotherapy and the toxicity profile is limited to case 
reports or extrapolation of radiotherapy salvage after surgical 
resection and thus poorly understood.2–4 This report describes 
our institutional experience and management paradigm for 
regional failures.
MATERIALS AND METHODS
Data Acquisition
Between 2003 and 2011, 12 patients among 160 treated 
with SBRT or accelerated hypofractionated radiotherapy 
(AHRT) for stage I and node negative stage II non–small-cell 
lung cancer met study criteria. A retrospective chart review 
was conducted of all patients and 25 suffered recurrence 
within the hilar or mediastinal lymph nodes. Each patient was 
restaged with diagnostic computed tomography (CT), and 
positron emission tomography (PET)/CT imaging and had 
biopsy-proven disease. Of the 25 patients with regional recur-
rence, 15 had isolated mediastinal failure (IMF) and 12 were 
treated with definitive and curative intent. IMF was defined 
as disease within the ipsilateral hilum and/or sites within the 
mediastinum in the absence of local recurrence of the origi-
nally targeted lung lesion or sites outside of the original lobe 
treated, including other lobes, contralateral lung, or sites out-
side the thorax.
Salvage EBRT Treatment
Gross disease only was targeted based on PET/CT and 
diagnostic CT imaging. No additional expansion was made for 
a clinical target volume, and no elective nodal irradiation was 
employed. A standard 0.5 to 1 cm planning target volume was 
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applied. Dosimetric parameters including field arrangement, 
beam energy, and customized blocking to cover the tumor or 
spare nearby critical structures were based on the judgment of the 
treating radiation oncologist. Composite plans were generated of 
current and prior courses in 10 of the 12 patients. An illustration 
of an initial, salvage, and composite plan with associated internal 
target volume and planning target volume (PTV) contours, as 
well as relevant isodose curves, is shown in Figure 1.
Initial treatments included SBRT (10 patients), AHRT 
(two patients), and AHRT/SBRT (one patient with bilateral 
stage I cancers). AHRT was selected as the treatment choice 
based on the location and size of the lesion at the discretion 
of the treating physician. Median time interval between initial 
and salvage course was 15 months with a range of 2 to 57 
months. The median salvage EBRT dose was 66 Gy and 33 
fractions with concurrent or sequential chemotherapy deliv-
ered in two and one patient, respectively. The average compos-
ite maximum dose combining the initial and retreatment plan 
was 90 Gy (range, 73–145 Gy). The mean composite lung 
V20 was 25% (range, 13%–29%) and mean esophageal dose 
was 10.7 Gy (range, 3.4–33 Gy).
Follow-Up and Statistical Analysis
Patients were considered to have failed locally after evi-
dence of increased size of enhancing tumor in the originally 
treated region or within the same lobe of the lung. Patients were 
screened for regional failures defined as new nodal disease in 
the hilum or mediastinum, including the area targeted at time 
of salvage EBRT. Distant failures were defined as disease in the 
contralateral lung or in sites outside of the thorax. PET scans and/
or biopsy was employed to assist with differentiating radiation 
related lung changes with local or regional recurrence. Toxicity 
was gathered retrospectively and scored per the Common 
Terminology Criteria for Adverse Events (CTCAE v4.0).
Time to event data was recorded from date of salvage 
EBRT completion for all measures except local control 
(LC), where the date of original SBRT or AHRT comple-
tion was used. Kaplan–Meier estimates were completed for 
 progression-free survival (PFS), overall survival (OS), LC, 
regional control, and distant control (DC)..
RESULTS
Patients
Table 1 outlines all 12 patients treated for IMF. Ten were 
treated with stage IA disease initially, whereas two patients 
were treated for T3N0 tumors, both with two separate lesions 
in the same lobe. Average tumor size for the initial treatment 
was 1.5 cm with a range of 0.7 to 2.8 cm. The locations of the 
regional failures were as follows: isolated hilar failure in three 
patients, single ipsilateral mediastinal station in four patients, 
hilar and single mediastinal station in two patients, and mul-
tiple mediastinal stations in three patients. The median age at 
salvage treatment was 66.
LC, Regional Control, DC, PFS, and OS
Median follow-up was 10 months with a range of 2 to 
49 months. A single patient failed within the same lobe treated 
FIGURE 1.  Illustration of initial treatment, salvage 
treatment, and composite radiation plan. ITV, inter-
nal target volume; PTV, planning target volume.
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66 months after the initial SBRT course yet after the salvage 
radiation course and was scored as local relapse while also 
suffering synchronous brain metastases. No regional failures 
occurred after the salvage radiation course. The local and 
regional failure-free survival at 2 and 5 years was 100% and 
92%, respectively.
Distant relapses were noted in five of the 12 patients 
(42%). The estimated 1- and 2-year DC was 56% and 38%, 
respectively. The 2-year PFS rate was identical to the DC rate 
with a median PFS of 14 months (95% confidence interval 
[CI], 5–49 mo). At the time of this analysis, four patients died 
following distant relapse, three have died without recurrence, 
one is alive with documented distant relapse, and four are 
alive with no sign of disease (Fig. 2). The estimated 1- and 
2-year OS was 58% and 29%, respectively, with a median of 
15 months (95% CI, 6–37 mo). The median OS from original 
treatment was 38 months (95% CI, 17–71 mo).
Toxicity
Four of the 12 patients (33%) experienced grade 2 acute 
or late toxicity, whereas one patient suffered late grade 3 tox-
icity from the salvage course of radiation. Acute grade 2 toxic-
ity was seen in four patients mainly related to esophagitis. Two 
patients experienced late toxicity with one requiring supple-
mental oxygen (grade 3) and one with sustained dysphagia 
(grade 2) (Table 2).
DISCUSSION
This brief report focuses on the management of regional 
recurrences in early-stage lung cancer. Although regional fail-
ures occur in up to 15% of these patients,5–7 a minority will be 
candidates for further thoracic radiotherapy. Many will have 
synchronous local or distant failure or a performance status 
that precludes additional treatment.5 The crude IMF rate in our 
experience was 9%. Unfortunately, chemotherapy is unable to 
provide durable tumor control and has modest response rates 
at the cost of substantial toxicity.6 Salvage radiotherapy for 
recurrence after surgical resection has been described. Kelsey 
et al.4 reported on 25 patients with stage I disease treated for 
recurrence after surgery with radiotherapy or chemoradio-
therapy more than a 12-year period. Median survival was 17 
months, and the predominate first site of failure was distant. 
Their report is consistent with earlier reports for radiotherapy 
salvage after surgery and with our current series.3,4,7 Therefore, 
given the near certainty of progression with chemotherapy 
treatment and the postoperative radiotherapy salvage results, 
we routinely evaluate and treat patients with IMF with radio-
therapy as there is some hope for salvage.6
Interestingly, although not unexpectedly, outcomes for 
stage I/II patients at the time of IMF seem to mirror stage III 
disease measured from initial treatment. The median OS in 
cooperative group trials with locally advanced lung cancer has 
ranged from 12 to 24 months with distant relapse rates up to 
40%.8 Among our small cohort, median OS was 15 months, 
and five of the 12 patients (42%) experienced subsequent dis-
tant relapse. With the predominant pattern of failure being dis-
tant, this would argue for chemotherapy in this scenario either 
concurrently or sequentially.TA
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Although IMF is uncommon, providers are reluctant 
to consider retreatment out of concern for toxicity in part 
based on data for retreatment at the same site in the thorax.9 
Multiple reports have detailed reirradiation focusing mainly 
on local failure as opposed to regional failure with either sal-
vage surgery,10,11 radiation,12–14 or even SBRT.15 Nevertheless, 
although reirradiation at the same location carries substan-
tial risk, the mediastinum has generally not received a pro-
hibitive dose after SBRT or AHRT as demonstrated in our 
composite dosimetry. The low V20 and mean esophageal 
rates reflect the small fields used in SBRT and the avoidance 
of dose spillage from the initial plan into the mediastinum. 
Furthermore, our low acute toxicity rate of 33% grade 2 and 
0% grade 3 highlights the separation geographically of the 
treatments and thus its safety. We suggest targeting gross 
disease only at salvage omitting elective coverage of the 
hilum or adjacent areas in the mediastinum. This decision 
appears well justified when viewed in context with the data 
demonstrating safe omission of elective nodal irradiation in 
stage III patients, the present study’s low toxicity rates paired 
with our excellent control rates.
CONCLUSIONS
Although IMF after SBRT or AHRT is uncommon, 
patients can be salvaged safely and effectively with fraction-
ated EBRT. Although a small sample size hinders our ability 
to draw definitive conclusions, making the parallel to stage III 
lung cancer, concurrent chemotherapy should be considered 
given the high distant failure rate if the patient’s performance 
status permits.
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